Orforglipron

Orforglipron is an oral, nonpeptide small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist approved as Foundayo tablets for glycemic control, weight loss, and type 2 diabetes management.

Brief glance

The primary outcome is Weight Loss, but it's also used for Metabolic. This compound is considered a Small Molecule. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.

Overview

Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly for weight loss and type 2 diabetes management. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central nervous system effects, leading to significant reductions in HbA1c (up to 2.2%) and body weight (up to 9.2% more than oral semaglutide). FDA-approved for adults with obesity or overweight plus weight-related conditions, it offers a convenient once-daily pill alternative to injectables.

Orforglipron (LY3502970) is a novel, orally bioavailable, nonpeptide small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1 RA), rationally designed to overcome the poor oral bioavailability and enzymatic degradation of peptide-based GLP-1 therapies. Its rigid polycyclic heteroaromatic structure provides chemical stability in the acidic gastric environment, resistance to proteases like DPP-4, and efficient gastrointestinal absorption, enabling once-daily dosing without food or water restrictions. Unlike peptide agonists that bind the orthosteric extracellular pocket, orforglipron acts as an allosteric agonist in a transmembrane pocket, stabilizing an active receptor conformation for Gs-biased signaling that promotes insulin secretion, blood sugar reduction, appetite suppression, and weight loss comparable to injectables. Developed by Eli Lilly as an investigational treatment for type 2 diabetes and obesity, it demonstrated about 12% average body weight reduction in trials and is positioned as a patient-friendly oral alternative to injections.

Benefits

Orforglipron, an oral small-molecule GLP-1 receptor agonist, produces significant reductions in HbA1c (1.3-1.6% over 40 weeks) and body weight (up to 17 pounds at higher doses) in patients with type 2 diabetes, with about 65% achieving HbA1c below 6.5% and 80% experiencing at least 5% weight loss.¹,² It enhances β-cell function (HOMA-B increases up to 132%), improves insulin sensitivity (HOMA-IR decreases up to 23%), and favorably alters biomarkers like IGFBP-2, adiponectin, and cardiovascular risk factors.²,³ In phase 3 trials such as ATTAIN-MAINTAIN, it superiorly maintains weight loss (retaining all but 0.9 kg after switching from injectables like semaglutide or tirzepatide) over 52 weeks as an adjunct to diet and exercise.⁴,⁵ These effects stem from glucose-dependent insulin secretion, glucagon suppression, and appetite reduction, supporting its role in managing type 2 diabetes and obesity.²

Side effects

Orforglipron, an oral GLP-1 receptor agonist, commonly causes gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, indigestion, stomach pain, abdominal distension, gas, belching, heartburn, fatigue, headache, and reduced appetite, which are typically mild to moderate, dose-related, and improve over time.⁶,⁷,⁸,⁹ Key safety considerations include a boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, contraindicating its use in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2.⁶,⁸ Serious risks encompass pancreatitis, severe gastrointestinal reactions, acute kidney injury due to dehydration, hypoglycemia (particularly with insulin or sulfonylureas), gallbladder problems, allergic reactions, diabetic retinopathy in type 2 diabetes patients, and pulmonary aspiration during anesthesia.⁶,⁷,⁸ Patients should seek immediate medical attention for severe abdominal pain, persistent vomiting, or symptoms suggesting pancreatitis.⁷,⁸

Mechanisms of action

Orforglipron is a small-molecule, nonpeptide allosteric agonist of the glucagon-like peptide-1 receptor (GLP-1R), a class B G-protein coupled receptor.²,¹⁰,¹¹ It binds with high affinity and selectivity to a transmembrane pocket involving helices TM1, TM2, TM3, TM7, and ECL2, distinct from the orthosteric site used by peptide agonists like native GLP-1, stabilizing an active receptor conformation that couples to Gs proteins.²,¹⁰ This activation stimulates adenylate cyclase to increase intracellular cAMP levels, activating protein kinase A and leading to glucose-dependent insulin secretion from pancreatic beta cells, suppressed glucagon release from alpha cells, delayed gastric emptying, and reduced appetite via central nervous system effects.²,¹⁰,¹¹ Unlike endogenous GLP-1, which is rapidly degraded by DPP-4, orforglipron resists enzymatic breakdown, enabling sustained receptor activation and oral bioavailability with a potential Gs-biased signaling profile that favors metabolic efficacy over receptor internalization.²,¹⁰